secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAge Labs, Inc. (BIOA)
CIK:        0001709941
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-269986
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAge Q3 net loss $20.2M; first participant dosed in BGE-102 Phase 1 trial
---------------------------------------------------------------------------

- Net loss of $20.2M ($0.56 EPS) vs $23.4M ($6.70) in Q3 2024; collaboration revenue $2.1M from Novartis deal.
- Cash, equivalents, and marketable securities $295.9M as of Sept 30, 2025, expected to fund operations through 2029.
- First participant dosed in Phase 1 trial of oral NLRP3 inhibitor BGE-102; initial SAD data expected by year-end 2025.
- Oral and parenteral APJ agonist programs on track for IND submissions in 2026; U.S. provisional patent filed May 2025.
- Partnerships with Novartis and Lilly advancing as expected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1709941/000119312525269986/0001193125-25-269986-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1709941/000119312525269986/bioa-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-269986

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer